Examkin

Soru

Zorluk: KolayMonitoring and Treatment Evaluation

A 30-year-old man with a history of severe, treatment-resistant schizophrenia is brought to the clinic by his family for a follow-up appointment. His psychiatrist recently transitioned him to clozapine after trials of multiple other antipsychotic medications failed to control his auditory hallucinations and severe paranoia. The patient is currently doing well, reports significant improvement in his symptoms, and denies any fever, sore throat, or fatigue. As part of the mandatory surveillance protocol for this medication, which of the following parameters must be evaluated weekly during his first six months of therapy?

  1. Absolute neutrophil countCevap
  2. B
    Glycosylated hemoglobin (HbA1c)
  3. C
    Corrected QT interval (QTc)
  4. D
    Serum drug concentration
  5. E
    Hepatic aminotransferases

Cevap

Absolute neutrophil count
The correct answer is the absolute neutrophil count (ANC). Clozapine is an effective atypical antipsychotic used for treatment-resistant schizophrenia, but it carries a well-documented risk of life-threatening agranulocytosis. To mitigate this risk, patients must be enrolled in a strict monitoring program. The standard surveillance protocol mandates that the ANC must be checked weekly during the first 6 months of treatment. If the ANC remains acceptable, the frequency decreases to every 2 weeks for the next 6 months, and then every 4 weeks for the duration of therapy.

Adım Adım Çözüm

1
Identify the newly initiated medication and its clinical context.
The patient was recently started on clozapine for treatment-resistant schizophrenia.
Recognizing the specific pharmacotherapy dictates the required adverse effect monitoring protocol.
2
Recall the major life-threatening adverse effects associated with this specific medication.
Clozapine is uniquely associated with a 1% to 2% risk of agranulocytosis (severe neutropenia).
Identifying the most dangerous adverse effect helps determine the most critical monitoring requirement.
3
Determine the mandated surveillance schedule required to safely monitor for this adverse effect.
The Risk Evaluation and Mitigation Strategy (REMS) program requires monitoring the absolute neutrophil count (ANC) weekly for the first 6 months, biweekly for the next 6 months, and monthly thereafter.
Guidelines explicitly require this timeline to prevent fatal infections associated with agranulocytosis.

Anahtar Kavram

Mandatory absolute neutrophil count (ANC) monitoring protocol for patients initiated on clozapine therapy.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru